Clinical Trial Highlights

• Rosuvastatin Reduces Primary Cardiovascular Events in Apparently Healthy Individuals with Elevated C-Reactive Protein Levels
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)
• Vitamin E and C Supplements Do Not Reduce Long-Term Cardiovascular Risk
• Phase 2 Trial Provides Safety and Outcomes Data on Novel Anticoagulant Agent
• Drug-Eluting Stents Prevent Death, MI, and Revascularization in Patients with Diabetes
• Early Invasive Management Beneficial for High-Risk NSTEMI Patients
• Tailored Clopidogrel Dosing Reduces Adverse Events in Patients with Clopidogrel Resistance Undergoing PCI
• I-PRESERVE Trial Fails to Find Clinical Benefit of Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
• Mid-Regional Pro-Adrenomedullin Test Predicts 90-Day Mortality after Heart Failure
• Home Anticoagulation Monitoring is Safe for Patients with Atrial Fibrillation or Mechanical Heart Valves
• No Significant Benefit with Rosiglitazone in Preventing Progression of Atherosclerosis in Diabetic Patients with a History of Cardiovascular Disease